• Hub Login
  • Contact
  • Investors
  • Viveve Solutions
    • Viveve System
    • InControl by Viveve
  • Clinical Studies
  • About
    • Mission
    • Leadership
    • Careers
  • News
    • Blog
    • Media & Press
    • Investor News
    • Events
  • Testimonials
Select Page
Dev Site

A Global Women’s Intimate Health Company

Press Releases

Investors
  • Overview
  • News / Events
    • Overview
    • Press Releases
    • Publications
    • IR Calendar
    • Analyst Coverage
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Clinical Advisory Board
    • Medical Consultants
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Investor Presentation
    • Contacts
    • RSS News Feed
  • News / Events

  • Overview
  • Press Releases
  • Publications
  • IR Calendar
  • Analyst Coverage
  • Email Alerts

Viveve to Host Conference Call to Provide Corporate Update and Third Quarter 2019 Results on November 7, 2019

Oct 24, 2019

Viveve Raises $6.76 million Through Completion of At-The-Market Equity Financing

Oct 1, 2019

Viveve Submits Investigational Testing Application to Conduct Short-Term Feasibility Study in Stress Urinary Incontinence

Sep 19, 2019

Viveve Announces Reverse Stock Split to Regain NASDAQ Compliance

Sep 18, 2019

Viveve to Present at the Ladenburg Thalmann 2019 Healthcare Conference

Sep 17, 2019

Viveve to Present at the H.C. Wainwright 21st Annual Global Investment Conference

Sep 3, 2019

Viveve Signs Exclusive Distribution Partnership with Paragon Meditech in Hong Kong, China and Macau

Sep 3, 2019

Viveve Signs Exclusive Distribution Partnership in Canada with Salient Medical Solutions

Aug 22, 2019

Viveve Reports Second Quarter 2019 Financial Results and Provides Corporate Update

Aug 8, 2019

Viveve Reports Additional Clinical Results of LIBERATE-International Trial for Stress Urinary Incontinence

Aug 7, 2019
RSS
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...30

    Solutions

    • Viveve System
    • InControl Products
    • Common Conditions

    About

    • Mission
    • Leadership
    • Contact Us
    • Investor Information

    News

    • Viveve Blog
    • Events
    • News & Publications
    • Testimonials

    Resources

    • Hub Login
    • Careers with Viveve
    • Support Center
    Dev Site
    345 Inverness Drive South • Building B, Suite 250 • Englewood, CO 80112
    The Viveve® System is an internationally patented cryogen-cooled, monopolar radiofrequency (CMRF) energy-based device. It has received regulatory approvals and clearances in many countries throughout the world and is available through physician import license in Japan. Country-specific approved indications include: • In Argentina the Viveve System is indicated for the treatment of urinary incontinence, vaginal laxity, and sexual function. • In Australia, Brazil, Canada, Chile, Colombia, Costa Rica, Dominican Republic, Hong Kong, Japan, Mexico, Panama, Philippines, Singapore, Uruguay, and Venezuela the Viveve System is indicated for the treatment of the vaginal introitus, after vaginal childbirth, to improve sexual function. • In the EU, Bahrain, Iceland, Korea, Kuwait, Lebanon, Liechtenstein, Norway, South Africa, Switzerland, and Ukraine the Viveve System is indicated for the treatment of vaginal laxity. • In Peru, Taiwan, and the United States the Viveve System is cleared for general surgical procedures for electrocoagulation and hemostasis.